In recent years, a variety of molecularly targeted drugs have been introduced, bringing new hope to breast cancer patients. The clinical application of targeted drugs has indeed improved the quality of life and prolonged the survival of many patients with advanced breast cancer. However, targeted drugs also have their “shortcomings”. Firstly, they are expensive and difficult to be widely available. Secondly, the current targeted therapy does not have a curative effect and is not effective for all patients. Moreover, most patients will develop drug resistance after applying molecular targeted drugs for a period of time, the mechanism of which is related to the mutation of molecular target genes and the inability to remove tumor stem cells. In addition, there are some toxic side effects of molecular targeted drugs, which generally do not require special treatment, and serious ones can be treated symptomatically or reduced or discontinued, but some of them can be fatal if not treated timely. The most common side effects of molecular targeted drugs are rash-like reactions, which occur on the head, neck, face and trunk. In addition, there will be gastrointestinal side effects such as mild to moderate diarrhea and nausea, and liver function impairment such as elevated transaminases, etc. There may also be cardiotoxicity, hematocrit and allergic reactions.